Tagged with ROche

Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…

Top 10 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American firm, Celgene. Made with Visme Infographic Maker

Switzerland Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful in the company’s history.   2018 was a good year for Roche. The Swiss-headquartered pharma giant saw seven percent overall…

Algeria A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both for companies that establish direct manufacturing footprints via joint ventures and those that employ the services of local contract manufacturers.…

Malaysia Lance Duan, general manager of Roche Malaysia, discusses the dynamic changes in the country’s health system and the possibilities that exist for Roche to establish a collaborative relationship with the new government. Duan also describes the many initiatives Roche has to support Malaysian patients from a varying degree of angles,…

Algeria Amine Sekhri, country manager for Roche Algeria discusses the potential for personalized precision medicine in Algeria and Roche’s important position within the Algerian market Could you please start by introducing yourself to our readers? This is actually my first role as a country manager. I am a physician, started my…

brexit Last week, Roche Boss Severin Schwan expressed concern that Brexit could further slow the UK drug approval process. After the UK’s recent divorce from the EMA, officials are in unknown territory. With only six months until the UK leaves the EU, the UK government has advised drug makers to stockpile…

Hong Kong Dr. Daniel Thurley, general manager of Roche Hong Kong and Macau, shares his first impressions of the affiliate, the strategic significance of Hong Kong to Roche globally, the innovative medicines and technology Roche is committed to bringing to Hong Kong, and his insights on Roche’s commitment to patient-centricity. There have…

Turkey In Summer 2018, we spoke to Adriano Antonio Treve, then general manager of Roche Turkey, now Area Head Central Eastern Europe, Turkey, Russia, Central Asia, Iran, Pakistan & Indian Subcontinent. Treve provided insights into the main opportunities and challenges of the Turkish market, Roche’s unrivalled commitment to making a difference…

UK Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse stakeholder groups, improving outcomes for UK patients.   We do see a will and an intent from stakeholders, from government…

UK Geoff Twist, managing director of Roche Diagnostics UK and Ireland, analyses the changing mindset he sees at various levels, leaning towards greater recognition of pathology’s impact on health systems. He further highlights some exciting paths Roche Diagnostics is embarking on, such as digital pathology and widened molecular screening programmes. After…

Roche Consuelo Martín de Dios, managing director of the Roche Institute Foundation discusses the legacy and movements of the organization as well as the challenges, opportunities, and future of Personalized Precision Medicine in Spain. What is the background of the Roche Institute Foundation in Spain? What have been the key milestones…